Tom Powles (@tompowles1) 's Twitter Profile
Tom Powles

@tompowles1

Interested in Urology Cancers, biomarkers and drug development.

ID: 1206580727296544769

calendar_today16-12-2019 14:24:22

1,1K Tweet

12,12K Takipçi

62 Takip Edilen

Tom Powles (@tompowles1) 's Twitter Profile Photo
Tom Powles
@tompowles1

a year ago

Phase 1/2 Design of the HIF2a inhibitor NKT2152-101 showed response rate of 20% with an ‘in class’ toxicity profile #ESMO24 . The long half like makes it distinct and there in now a dose to take to randomised trials. Advantages over belzurifan are unclear. 2 doses being pursued.

Phase 1/2 Design of the HIF2a inhibitor NKT2152-101 showed response rate of 20% with an ‘in class’ toxicity profile #ESMO24 . The long half like makes it distinct and there in now a dose to take to randomised trials. Advantages over belzurifan are unclear. 2 doses being pursued.